Investor Presentaiton
Generics and Consumer Health EUR 517.6 million (-7.1%)
MEUR
450
419.8
400
386.7
350
300
250
•
Sales split by geographic
9%
16%
areas
0
200
150
137.3130.9
15%
100
50
0
Generic
prescription drugs
Self-care products
2022
2023
60%
■Finland and Baltics Scandinavia
■Eastern Europe
■ROW
•
•
ORION
Generic competition pressing
the prices and sales of Simdax®
and dexmedetomidine products
for human use
Discontinuation of business
operations in Russia also
explains the net sales decline
Excluding Simdax®,
dexmedetomidine products for
human use and Russia, net sales
development was positive →
underlying business was solid
In Finland, the sales of both
generic prescription drugs and
self-care products developed
well
35
Investor Presentation Orion Corporation
ROW Rest of the worldView entire presentation